A synthetic fragment corresponding to the C-terminal region of human growth hormone, originally advanced on the hypothesis that GH's lipolytic activity could be separated from its growth-promoting and glucose-perturbing activity. It does not raise IGF-1 and lacks GH receptor-mediated growth activity. The proposed lipolytic mechanism has not been firmly established.
This one has a clear answer, and it is negative. AOD-9604 progressed to Phase 2b trials in obesity and failed to separate from placebo on weight endpoints. It is one of the few peptides in this library with a definitive human efficacy result — and the result was no benefit.
Not FDA-approved. FDA has previously rejected attempts to market it as a dietary supplement, taking the position that it is a drug. Prohibited in sport (WADA S2).
Trial safety was relatively unremarkable — but a favourable safety profile in a drug that does not work is not a reason to use it.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.